Switch theme
Sign up to access all valuation multiples
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
2019
n/a
LTM Revenue $1.8M
LTM EBITDA n/a
$51.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Argenica Therapeutics has a last 12-month revenue of $1.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Argenica Therapeutics achieved revenue of n/a and an EBITDA of -$3.5M.
Argenica Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Argenica Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$3.0M | -$3.5M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$2.6M | -$3.0M | XXX | XXX | XXX |
| Net Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 17, 2025, Argenica Therapeutics's stock price is AUD 1 (or $0).
Argenica Therapeutics has current market cap of AUD 96.1M (or $60.8M), and EV of AUD 81.0M (or $51.2M).
See Argenica Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $51.2M | $60.8M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 17, 2025, Argenica Therapeutics has market cap of $60.8M and EV of $51.2M.
Argenica Therapeutics's trades at 29.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Argenica Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Argenica Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $51.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpArgenica Therapeutics's NTM/LTM revenue growth is -100%
Argenica Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Argenica Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Argenica Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Argenica Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Argenica Therapeutics acquired XXX companies to date.
Last acquisition by Argenica Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Argenica Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Argenica Therapeutics founded? | Argenica Therapeutics was founded in 2019. |
| Where is Argenica Therapeutics headquartered? | Argenica Therapeutics is headquartered in Australia. |
| Is Argenica Therapeutics publicy listed? | Yes, Argenica Therapeutics is a public company listed on ASX. |
| What is the stock symbol of Argenica Therapeutics? | Argenica Therapeutics trades under AGN ticker. |
| When did Argenica Therapeutics go public? | Argenica Therapeutics went public in 2021. |
| Who are competitors of Argenica Therapeutics? | Similar companies to Argenica Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Argenica Therapeutics? | Argenica Therapeutics's current market cap is $60.8M |
| What is the current revenue of Argenica Therapeutics? | Argenica Therapeutics's last 12-month revenue is $1.8M. |
| What is the current EV/Revenue multiple of Argenica Therapeutics? | Current revenue multiple of Argenica Therapeutics is 29.0x. |
| Is Argenica Therapeutics profitable? | Yes, Argenica Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
